Evaluation of a calibrated (18)F-FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment.
J Nucl Med
; 52(8): 1218-26, 2011 Aug.
Article
en En
| MEDLINE
| ID: mdl-21764801
ABSTRACT
UNLABELLED Increasingly, clinical trials are being planned in patients with mild cognitive impairment (MCI) to prevent or delay the onset of dementia in Alzheimer disease (AD) by disease-modifying intervention. Inclusion of imaging techniques as biomarkers for patient selection and assessment of outcome is expected to increase trial efficacy. PET using (18)F-FDG provides objective information about the impairment of synaptic function and could, with appropriate standardization, qualify as a biomarker. METHODS:
We evaluated a predefined quantitative measure (PET score) that is extracted automatically from (18)F-FDG PET scans using a sample of controls (n = 44), patients with MCI (n = 94), and patients with mild AD (n = 40) from the Alzheimer Disease Neuroimaging Initiative (ADNI). Subjects received 4 scans and clinical assessments over 2 y.RESULTS:
PET scores provide much higher test-retest reliability than standard neuropsychologic test scores (Alzheimer's Disease Assessment Scale-Cognitive [ADAS-cog] and Mini-Mental State Examination) and superior signal strength for measuring progression. At the same time, they are related linearly to ADAS-cog scores, thus providing a valid measure of cognitive impairment. In addition, PET scores at study entry in MCI patients significantly predict clinical progression to dementia with a higher accuracy than Mini-Mental State Examination and ADAS-cog.CONCLUSION:
(18)F-FDG PET scores are a valid imaging biomarker to monitor the progression of MCI to AD. Their superior test-retest reliability and signal strength will allow the reduction in the number of subjects needed or shortening of study duration substantially.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Trastornos del Conocimiento
/
Fluorodesoxiglucosa F18
/
Tomografía de Emisión de Positrones
/
Enfermedad de Alzheimer
Tipo de estudio:
Prognostic_studies
Aspecto:
Patient_preference
Límite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Nucl Med
Año:
2011
Tipo del documento:
Article
País de afiliación:
Reino Unido